982
Index
Gastrointestinal secretions, drugs
affecting, 890–891, 896–913
adults, 899
children, 899
digestive enzymes, 896, 912–913
gastro-oesophageal reflux disease and
ulcer disease, 897–912
antacids.
See
Antacids
GI protectant, 896, 901, 909–910
histamine-2 antagonists.
See
Histamine-2 antagonists
prostaglandins, 901, 910–912
proton pump inhibitors.
See
Proton
pump inhibitors
older adults, 899
Gastrointestinal system, 888–894
antiemetic agents.
See
Antiemetic agents
function, 890–892
absorption, 891
digestion, 891
motility.
See
Gastrointestinal motility,
drugs affecting
secretion.
See
Gastrointestinal
secretions, drugs affecting
parasympathetic blockade, effects, 505
reflexes, 892–894
central, 893–894
local, 888, 892–893
structure, 889–892
Gastrointestinal toxicity, 87
Gate control theory of pain, 397, 399
Gefitinib, 219, 220, 221
Gelatin, absorbable, 767, 769, 770
Gemcitabine, 200, 201, 203
Gemeprost, 620, 622
Gemfibrozil, 738, 745
Gender
drug effects and, 25, 26
General anaesthesia, 417–419
administration, 418–419
agents, 419–424
anaesthetic gases, 420, 421–422
barbiturate anaesthetics, 419–420
care considerations, 423–424
non-barbiturate anaesthetics,
420–421
volatile liquids, 420, 422–423
balanced, 418
induction, 419
maintenance, 419
recovery, 419
risk factors, 417–418
Generalised seizure, 352, 355
drugs for treating, 356–363
Generic drugs, 2, 5, 7, 9–10
cost considerations, 65–66
Generic name, 2, 5, 7
Genes, 72, 73
Genetic engineering, 2, 5
Genetic factors
drug effects and, 25, 26
Gentamicin, 90, 95, 96, 957
Gentian violet, 157
Giardiasis, 163, 172
Gigantism, 521, 528
Ginger, 964
Ginkgo, 205, 965
Ginseng, 471, 582, 965
Glands, 512–515
Glatiramer acetate, 263, 264
Glibenclamide, 573, 586–588
Gliclazide, 586, 587
Glimepiride, 586, 587
Glipizide, 586, 587
Glomerulus, 794, 796
glomerular filtration, 15, 23, 797
Glucagon, 572, 573, 575, 589–592
Glucagon-like polypeptide-1, 572, 573,
574, 586, 588–589
Glucocorticoids, 536, 539–545
adverse effects, 543
care considerations, 544–545
contraindications and cautions, 543
children, 543
elderly people, 543
drug–drug interactions, 543
duration of effect, 539
pharmacokinetics, 540, 543
routes of administration, 544
therapeutic actions and indications,
540
Glucosamine, 965
Glucose (generic), 806, 814
Glucose levels, controlling, 572–592,
809–810
adults, 574
alterations in glucose metabolism,
36–37
children, 574
diabetes mellitus, 572, 573, 576–578
cultural blood glucose variations, 577
hyperglycaemia, 578
hypoglycaemia, 578
fixed-combination oral agents, 589
glucose-elevating agents, 591–592
adverse effects, 592
care considerations, 592
contraindications and cautions, 591
drug–drug interactions, 592
pharmacokinetics, 591
therapeutic actions and indications,
591
glucose regulation, 573–576
glucagon, 575
insulin, 574–575
loss of blood glucose control, 575–576
miscellaneous factors, 575
pancreas, 573
insulin, 572–593
adverse effects, 581
care considerations, 582–583
contraindications and cautions, 579,
581
delivery, 580, 581
diabetes mellitus (type I), 584–585
drug–drug interactions, 581–582
name confusion, 579
pharmacokinetics, 579
therapeutic actions and indications,
579, 581
mechanisms, 575
older adults, 574
oral hypoglycaemic agents, 586–587,
588–591
care considerations, 590–591
stress and, 577
sulfonylureas, 573, 585–588
adverse effects, 588
contraindications and cautions, 588
drug–drug interactions, 588
first generation, 587
pharmacokinetics, 588
second generation, 587
therapeutic actions and indications,
587–588
Glycerol, 920
Glyceryl trinitrate, 716–719
administration, 718
Glycogen, 572, 574
Glycogenolysis, 455, 457
Glycopyrrolate, 501, 503
Glycosuria, 572, 575
Glycosylated haemoglobin, 572, 576
Gold
compounds, 252–253
adverse effects, 252
contraindications and cautions, 252
drug–drug interactions, 253
pharmacokinetics, 252
therapeutic actions and indications,
252
therapeutic effect, 5
Gold sodium thiomalate, 252, 253
Goldenrod leaves, 965
Goldenseal, 471, 965
Golgi apparatus, 72, 75
Golimumab, 265, 266
Gonadotropin-releasing hormone
(GHRH), 522
Goserelin, 212, 214, 523, 524
Gotu kola, 965
Gram-negative bacteria, 90, 91
Gram-positive bacteria, 90, 91
Granisetron, 932, 934
Grape seed extract, 965
Green tea leaf, 965
Griseofulvin, 151, 153, 155
Growth hormone agonists, 521, 525–528
adverse effects, 527
care considerations, 527–528
contraindications and cautions, 527
drug–drug interactions, 527
new delivery system, 527
pharmacokinetics, 527
therapeutic actions and indications, 526
Growth hormone antagonists, 528–530
adverse effects, 529
care considerations, 529–530
contraindications and cautions,
528–529
drug–drug interactions, 529
pharmacokinetics, 528
therapeutic actions and indications,
528
Growth hormone therapy, 526
Guaifenesin, 842, 857–858
Guarana, 965
Guayusa, 965
